🔗 Share this article

As the United States proceeds with historic adjustments to its vaccination schedules, a particular individual appears somewhat surprisingly: Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about Covid vaccines in the pandemic and has focused upon potential deaths after COVID-19 immunization in her short position at the FDA.

Planned Shifts to Childhood Immunization Schedule

Public health authorities had intended to unveil sweeping changes to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US at odds with many the global community with little proof for improved outcomes. The announcement has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is listed to present at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the division this year.

A New Direction at the Agency

Høeg's temporary position could signify a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing certain childhood vaccine recommendations in the US in order to be more in line with the Danish model, a society with universal health coverage and a citizenry about the population of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccines – usually the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Qualifications

Høeg has no apparent background in pharmaceutical research, oversight or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She appears not to have the necessary background” for running the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a large organization. She is not an expert in drug approvals.”

Previous commissioners of CBER would “be deeply familiar with legal statutes and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that former directors who led CBER have had.”

This division has an enormous workload at the FDA, Woodcock pointed out.

“The public just focuses on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There’s a biosimilars division, OTC medication office and so forth, and each of these must be supervised,” Woodcock noted. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a major leadership element to the position, which manages more than 5,000 staff members. “It’s a massive leadership role, if you execute it properly,” the former official concluded.

Agency Reaction and Disputed Programs

In response to inquiries about Dr. Høeg's fitness for the role and whether this assignment represents greater collaboration among agency officials on vaccines, a representative stated that the “concerns rely on flawed presumptions”.

“Her experience aligns with the duties of her role,” the spokesperson explained, pointing to the period Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's new expedited review system, a disputed expedited therapy clearance system that allegedly troubled her predecessors. “How are these drugs being chosen for this expedited pathway? Who takes the choices?” Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

In general, he remarked, “the agency appears to be shifting towards laxer rules of all drugs, aside from immunizations.”

Public Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, past, Howard observe. She published a study using non-validated crowd-sourced reports to estimate the rate of heart inflammation following Covid vaccination. She consulted for the Florida top health official Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccines are riskier than they are.

Among her “desired changes” for the new government encompassed changing rules for novel immunizations and halting “non-essential” immunizations, she stated post-election on a audio program. At the agency, Dr. Høeg has reportedly floated the idea of excluding adolescent males from obtaining COVID-19 vaccinations.

“She is an thorough true believer who begins with her conclusions and works backwards to retrofit the science in a very disingenuous, fraudulent way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other dissenters, {like|